Allegis Investment Advisors LLC Has $1.69 Million Stake in Maximus, Inc. (MMS)
Allegis Investment Advisors LLC decreased its position in Maximus, Inc. (NYSE:MMS) by 2.9% during the second quarter, Holdings Channel reports. The institutional investor owned 26,974 shares of the health services provider’s stock after selling 817 shares during the period. Allegis Investment Advisors LLC’s holdings in Maximus were worth $1,689,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Neuburgh Advisers LLC raised its stake in Maximus by 1.9% in the first quarter. Neuburgh Advisers LLC now owns 1,696 shares of the health services provider’s stock worth $105,000 after buying an additional 32 shares in the last quarter. Acrospire Investment Management LLC raised its stake in shares of Maximus by 183.3% in the first quarter. Acrospire Investment Management LLC now owns 1,700 shares of the health services provider’s stock valued at $106,000 after buying an additional 1,100 shares during the period. Glen Harbor Capital Management LLC raised its stake in shares of Maximus by 1.9% in the first quarter. Glen Harbor Capital Management LLC now owns 2,332 shares of the health services provider’s stock valued at $145,000 after buying an additional 44 shares during the period. First Bank & Trust raised its stake in shares of Maximus by 4.2% in the second quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock valued at $157,000 after buying an additional 101 shares during the period. Finally, Elkfork Partners LLC raised its stake in shares of Maximus by 1.9% in the first quarter. Elkfork Partners LLC now owns 2,968 shares of the health services provider’s stock valued at $185,000 after buying an additional 56 shares during the period. Institutional investors own 97.20% of the company’s stock.
Shares of Maximus, Inc. (NYSE:MMS) opened at 60.32 on Wednesday. Maximus, Inc. has a one year low of $43.69 and a one year high of $64.97. The firm has a 50-day moving average of $61.06 and a 200 day moving average of $60.99. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of 19.33 and a beta of 1.39.
Maximus (NYSE:MMS) last released its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.03. The company had revenue of $600.40 million during the quarter, compared to analysts’ expectations of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.79 EPS. On average, equities research analysts predict that Maximus, Inc. will post $3.12 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 31st. Shareholders of record on Tuesday, August 15th will be given a $0.045 dividend. The ex-dividend date is Friday, August 11th. This represents a $0.18 annualized dividend and a yield of 0.30%. Maximus’s dividend payout ratio (DPR) is 5.73%.
Several analysts have commented on the stock. KeyCorp restated a “sector weight” rating on shares of Maximus in a report on Thursday, May 25th. ValuEngine lowered shares of Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th. Canaccord Genuity lowered shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective for the company. in a report on Tuesday, July 4th. BidaskClub lowered shares of Maximus from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Maximus from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating and eight have issued a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $62.17.
In other Maximus news, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $62.81, for a total value of $1,884,300.00. Following the completion of the sale, the chief executive officer now directly owns 584,114 shares of the company’s stock, valued at approximately $36,688,200.34. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, President Bruce Caswell sold 8,000 shares of the business’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $61.79, for a total transaction of $494,320.00. Following the completion of the sale, the president now directly owns 35,904 shares of the company’s stock, valued at $2,218,508.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,139 shares of company stock valued at $6,253,509. 3.10% of the stock is owned by corporate insiders.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS).
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.